首页> 美国卫生研究院文献>other >Post-modification of preformed liposomes with novel non-phospholipid poly(ethylene glycol)-conjugated hexadecylcarbamoylmethyl hexadecanoic acid for enhanced circulation persistence in vivo
【2h】

Post-modification of preformed liposomes with novel non-phospholipid poly(ethylene glycol)-conjugated hexadecylcarbamoylmethyl hexadecanoic acid for enhanced circulation persistence in vivo

机译:用新型非磷脂聚(乙二醇) - 缀合的十六烷基氨基甲酰甲基十六甲酸的预成型脂质体的后改性用于增强循环持续存在的体内

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We report synthesis and characterization of a novel PEG2000-conjugated hexadecylcarbamoylmethyl hexadecanoate (HDAS-PEG) as a PEG-phospholipid substitute for enhancing circulation persistence of liposomes. HDAS-PEG showed critical micelle concentration of 4.25 μM. We used post-insertion technique to introduce HDAS-PEG in outer lipid layer of the preformed liposomes. The presence of surface HDAS-PEG was confirmed by altered electrophoretic mobility, confocal microscopy and PEG estimation by ELISA. The post-inserted HDAS-PEG desorbed at approximately half the rate at which post-inserted DSPE-PEG desorbed from the liposome surface. HDAS-PEG significantly reduced liposome-induced complement activation (C4d, Bb and SC5b); HDAS-PEG was more effective than more commonly used DSPE-PEG in this capacity. For studying circulation persistence, the liposomes were labeled with 99mTc radionuclide and administered in rats. 99mTc-HDAS-PEG-liposomes showed prolonged persistence in blood as compared to that shown by 99mTc-plain liposomes. After 24 h of administration, < 1% of 99mTc-plain liposomes remained in blood, whereas approximately 28% of injected 99mTc-HDAS-PEG-liposomes were present in blood. In comparison, only 4.8% of 99mTc-DSPE-PEG-liposomes was measured in blood after 24 h. As expected, the clearance route of the liposomes was through liver and spleen. These results demonstrate the potential of a novel non-phosphoryl HDAS-PEG for surface modification of preformed liposomes with a goal of prolonging their circulation persistence and more effective inhibition of complement activation.
机译:我们报告了合成和表征的新型PEG2000共轭十六烷基氨基甲酰基甲基十六烷酸酯(HDAS-PEG)作为PEG磷脂替代品,以增强脂质体的循环持久性。 HDAS-PEG显示临界胶束浓度为4.25μM。我们使用插入后技术将HDAS-PEG引入预先形成的脂质体的外脂质层中。表面HDAS-PEG的存在通过电泳迁移率的改变,共聚焦显微镜和ELISA的PEG估计得到了证实。插入后的HDAS-PEG的解吸速率约为插入后的DSPE-PEG从脂质体表面解吸速率的一半。 HDAS-PEG显着降低脂质体诱导的补体激活(C4d,Bb和SC5b);在这种能力下,HDAS-PEG比更常用的DSPE-PEG更有效。为了研究循环持久性,将脂质体用 99m Tc放射性核素标记并在大鼠中给药。与 99m Tc-普通脂质体相比, 99m Tc-HDAS-PEG-脂质体在血液中的持久性延长。给药24小时后, 99m Tc-蛋白脂质体中仍少于1%,而注射的 99m Tc-HDAS-PEG-脂质体中约有28%存在于血液中。血液。相比之下,在24小时后的血液中仅测量了4.8%的 99m Tc-DSPE-PEG-脂质体。不出所料,脂质体的清除途径是通过肝脏和脾脏。这些结果证明了新颖的非磷酰基HDAS-PEG用于预形成的脂质体的表面修饰的潜力,其目的是延长其循环持久性并更有效地抑制补体激活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号